Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase 2, Proof-Of-Concept, Multicenter, Randomized, Double-Blind, Placebo- Controlled, Study to Evaluate the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics and Efficacy of Pomalidomide (CC-4047) in Subjects With Systemic Sclerosis With Interstitial Lung Disease

NCT01559129 is registered in ClinicalTrials.gov with Celgene as lead sponsor.

NCT NCT01559129
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT01559129 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase 2, Proof-Of-Concept, Multicenter, Randomized, Double-Blind, Placebo- Controlled, Study to Evaluate the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics and Efficacy of Pomalidomide (CC-4047) in Subjects With Systemic Sclerosis With Interstitial Lung Disease
Lead sponsor
Celgene
Phase
Phase 2
Overall status
Terminated
Start date
August 9, 2012
Completion date
November 3, 2016
Enrollment
23 (actual)
Sites
56

Conditions

As the registry lists them; a condition with its own page is linked.

interstitial lung disease, scleroderma, systemic, sclerosis, systemic, systemic scleroderma, systemic sclerosis